Business Context and Reporting Period
Compugen Ltd. (NASDAQ: CGEN), a drug and diagnostic discovery company based in Tel Aviv, Israel, reported financial results for the third quarter ended September 30, 2003. The company focuses on merging computational technologies with molecular biology to discover therapeutic proteins and diagnostic tools. During the quarter, Compugen selected novel splice variants of four genes as initial in-house therapeutic development candidates and acquired substantial proprietary sequence data to enhance discovery efforts.
Key Financial Metrics
| Metric | Q3 2003 | Q3 2002 | YTD 9 Months 2003 | YTD 9 Months 2002 |
|---|---|---|---|---|
| Total Revenues | $1.95 million | $2.81 million | $7.47 million | $8.43 million |
| Net Loss | $3.19 million | $3.02 million | $7.90 million | $8.99 million |
| Net Loss Per Share | ($0.12) | ($0.11) | ($0.30) | ($0.34) |
| Cash, Equivalents & Marketable Securities | $64.8 million | N/A | N/A | N/A |
| Operating Expenses | $5.60 million | $6.57 million | $17.11 million | $19.39 million |
Liquidity: As of September 30, 2003, the company held $64.8 million in cash, cash equivalents, and marketable securities, comprising $19.6 million in current assets and $45.2 million in long-term marketable securities. Total current liabilities were $7.0 million.
Material Changes vs. Prior Period
- Revenue Decline: Q3 2003 revenues decreased 31% to $1.95 million from $2.81 million in Q3 2002. This was driven by a drop in product and services revenue from $2.35 million to $1.22 million, partially offset by an increase in R&D grants from $459,000 to $728,000.
- Expense Reduction: Total operating expenses decreased to $5.60 million in Q3 2003 from $6.57 million in Q3 2002. Notable reductions occurred in sales and marketing expenses ($699k vs $1.26M) and cost of products and services ($381k vs $832k).
- Non-Cash Charges: The Q3 2003 net loss included a $612,000 non-cash charge for amortization of deferred compensation, compared to $195,000 in the prior year quarter.
- YTD Improvement: For the first nine months of 2003, the net loss narrowed to $7.90 million from $8.99 million in the same period of 2002, despite lower revenues, due to significant expense management.
Outlook, Management Commentary, and Risks
Strategic Shifts: Management announced the transfer of the Bioccelerator product line to Biocceleration Ltd. to focus on drug and diagnostic discovery. The company is also considering the divestiture of other legacy tools and products. Management expects such transactions could reduce reported revenues but anticipates no material impact on cash flow or earnings.
Guidance Update: Compugen increased its year-end 2003 cash and cash-related accounts expectation by approximately $6-7 million, raising the previous target of $52 million.
Risks: Forward-looking statements are subject to risks including changes in collaborator relationships, competitive products, technological changes, and the ability to retain customers. The filing notes that actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the sustainability of the $728,000 in R&D grants included in Q3 revenue.
- Confirm the status and timeline of the potential divestiture of legacy tools and products.
- Review the specific details of the Bioccelerator transfer to Biocceleration Ltd. and any associated financial impacts.
- Assess the progress of the four selected therapeutic protein candidates and associated R&D burn rate.
- Validate the updated year-end 2003 cash position projection against current burn rates.